Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma.

Honkavuori-Toivola M, Santala M, Soini Y, Turpeenniemi-Hujanen T, Talvensaari-Mattila A.

Dis Markers. 2013;35(4):261-6.

2.

Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions.

Graesslin O, Cortez A, Uzan C, Birembaut P, Quereux C, Daraï E.

Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1911-7.

PMID:
17009991
3.

[Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].

Wei QY, Wu YQ, Fan SQ.

Hunan Yi Ke Da Xue Xue Bao. 2003 Jun;28(3):212-6. Chinese.

PMID:
14653069
4.

Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.

Hoikkala S, Pääkkö P, Soini Y, Mäkitaro R, Kinnula V, Turpeenniemi-Hujanen T.

Cancer Lett. 2006 May 8;236(1):125-32. Epub 2005 Jun 27. Erratum in: Cancer Lett. 2007 Mar 18;247(2):359.

PMID:
15982804
5.

Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.

Marečko I, Cvejić D, Tatić S, Dragutinović V, Paunović I, Savin S.

Cancer Biomark. 2011-2012;11(1):49-58. doi: 10.3233/CBM-2012-0258.

PMID:
22820140
6.

Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.

Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S.

Cancer. 1998 Apr 1;82(7):1359-66.

PMID:
9529029
7.

The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis.

Têtu B, Brisson J, Wang CS, Lapointe H, Beaudry G, Blanchette C, Trudel D.

Breast Cancer Res. 2006;8(3):R28. Epub 2006 Jun 15.

8.

Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels.

Davidson B, Reich R, Berner A, Givant-Horwitz V, Goldberg I, Risberg B, Kristensen GB, Trope CG, Bryne M, Kopolovic J, Nesland JM.

Eur J Cancer. 2001 Nov;37(16):2040-9.

PMID:
11597382
9.

[Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].

Fan SQ, Wei QY, Li MR, Zhang LQ, Liang QC.

Ai Zheng. 2003 Sep;22(9):968-73. Chinese.

PMID:
12969531
10.

[Expression of matrix metalloproteinase-2, 9 and it's tissue inhibitor-1, 2 in endometrial carcinoma].

Guo W, Chen G, Zhu C, Wang H.

Zhonghua Fu Chan Ke Za Zhi. 2002 Oct;37(10):604-7. Chinese.

PMID:
12487935
11.
12.

Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma.

Talvensaari-Mattila A, Santala M, Soini Y, Turpeenniemi-Hujanen T.

Anticancer Res. 2005 Nov-Dec;25(6B):4101-5.

13.

Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma.

Honkavuori-Toivola M, Talvensaari-Mattila A, Soini Y, Turpeenniemi-Hujanen T, Santala M.

Tumour Biol. 2012 Aug;33(4):935-41. doi: 10.1007/s13277-012-0321-7. Epub 2012 Jan 21.

PMID:
22270451
14.

Significant relation of tissue inhibitor of matrix metalloproteinase-2 and its combination with matrix metalloproteinase-2 to survival of patients with cancer of uterine cervix.

Wang PH, Ko JL, Yang SF, Tsai HT, Tee YT, Han CP, Lin LY, Chen SC, Shih YT.

Reprod Sci. 2011 Aug;18(8):798-808. doi: 10.1177/1933719111398143. Epub 2011 Mar 21.

PMID:
21422052
15.

High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma.

Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Berner A, Bryne M, Reich R.

Clin Exp Metastasis. 1999;17(10):799-808.

PMID:
11089877
16.
17.

Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.

Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T.

Anticancer Res. 2000 Mar-Apr;20(2B):1311-6.

PMID:
10810441
18.

Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.

Misugi F, Sumi T, Okamoto E, Nobeyama H, Hattori K, Yoshida H, Matsumoto Y, Yasui T, Honda K, Ishiko O.

Int J Mol Med. 2005 Oct;16(4):541-6.

PMID:
16142384
19.

Ratio of metalloproteinase 2 to tissue inhibitor of metalloproteinase 2 in medullary thyroid carcinoma.

Cavalheiro BG, Junqueira CR, Brandão LG.

Arch Otolaryngol Head Neck Surg. 2009 Aug;135(8):812-7. doi: 10.1001/archoto.2009.92.

PMID:
19687404
20.

High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.

Honkavuori M, Talvensaari-Mattila A, Puistola U, Turpeenniemi-Hujanen T, Santala M.

Anticancer Res. 2008 Sep-Oct;28(5A):2715-9.

Supplemental Content

Support Center